Skip to Content

Join the 'Tuberculosis - Resistant' group to help and get support from people like you.

Tuberculosis - Resistant News

Global Efforts to Combat TB Epidemic Falling Short

Posted 13 Oct 2016 by Drugs.com

THURSDAY, Oct. 13, 2016 – Countries around the world need to work harder to combat tuberculosis infections and deaths, a new World Health Organization report says. Nations across the globe have pledged to reduce tuberculosis (TB) infections by 80 percent and TB deaths by 90 percent by 2030, but they must work faster if they want to meet these goals, according to the WHO. "We face an uphill battle to reach the global targets for tuberculosis," WHO Director General Dr. Margaret Chan said in an organization news release. "There must be a massive scale-up of efforts, or countries will continue to run behind this deadly epidemic and these ambitious goals will be missed." Tuberculosis is a disease that mainly affects the lungs. The bacteria that cause TB are primarily spread from person to person through tiny droplets from coughs and sneezes. The global response to the TB epidemic did manage ... Read more

Related support groups: Tuberculosis, Rifampin, Tuberculosis - Latent, Ethambutol, Tuberculosis - Active, Pulmonary Tuberculosis, Tuberculosis - Prophylaxis, Pyrazinamide, Diagnosis and Investigation, Tuberculosis - Extrapulmonary, Rifamate, Isoniazid/Rifampin, Rifabutin, Tuberculosis - HIV Status Unknown, Tuberculous Meningitis, Myambutol, Rifater, Tuberculosis - Resistant, Mycobutin, Rifadin

Tuberculosis Decline in U.S. Has Stalled, CDC Reports

Posted 24 Mar 2016 by Drugs.com

THURSDAY, March 24, 2016 – Two decades of progress toward eliminating tuberculosis in the United States has stalled, with incidence of the lung disease holding steady from 2013 to 2015, a federal government report shows. "Resuming progress toward TB elimination in the United States will require intensification of efforts both in the U.S. and globally," said researchers from the U.S. Centers for Disease Control and Prevention's National Tuberculosis Surveillance System. If not treated, TB can be fatal. The bacterial infection is spread through the air, when someone infected coughs, sneezes or speaks. However, it is not easily transmitted – you must be in close contact with someone who has TB for a long period of time, according to the American Lung Association. Overall, TB incidence leveled off at about three new cases per 100,000 people each year between 2013 and 2015, according to ... Read more

Related support groups: Xifaxan, Tuberculosis, Rifampin, Rifaximin, Tuberculosis - Latent, Tuberculosis - Active, Pulmonary Tuberculosis, Tuberculosis - Prophylaxis, Tuberculosis - Extrapulmonary, Isoniazid/Rifampin, Rifamate, Rifabutin, Tuberculosis - HIV Negative, Rifater, Mycobutin, Tuberculosis - Resistant, Rifadin, Rifapentine, Tuberculosis - HIV Positive, Rimactane

Screen High-Risk Adults for Tuberculosis, Experts Say

Posted 8 Mar 2016 by Drugs.com

TUESDAY, March 8, 2016 – Adults at greater risk for latent tuberculosis infection should be screened for the condition, the U.S. Preventive Services Task Force recommends. "The task force recommends that primary care clinicians screen adults at increased risk for [latent TB] to help prevent the progression to active TB," panel member Dr. Francisco Garcia said in a task force news release. Garcia is director and chief medical officer of the Pima County Health Department in Tucson, Ariz. Tuberculosis, commonly known as TB, is an infection caused by bacteria. Anyone in close contact with someone with tuberculosis may be exposed to the bacteria. It spreads through the air when an infected person coughs or sneezes, according to the health panel. TB usually attack the lungs, but the bacteria can attack any part of the body such as the kidney, spine and brain. If it isn't treated properly, ... Read more

Related support groups: Tuberculosis, Tuberculosis - Latent, Tuberculosis - Active, Pulmonary Tuberculosis, Tuberculosis - Prophylaxis, Tuberculosis - Extrapulmonary, Tuberculosis - HIV Negative, Tuberculosis - Resistant, Tuberculosis - HIV Positive, Adrenal Tuberculosis

New TB Test May Help Simplify Diagnosis

Posted 20 Feb 2016 by Drugs.com

FRIDAY, Feb. 19, 2016 – A simple new blood test for tuberculosis may one day help improve diagnosis and treatment of the deadly disease in developing countries, researchers report. The inexpensive test identifies a gene expression "signature" that distinguishes people with active TB from those with either latent TB or other diseases, according to the research team from the Stanford University School of Medicine, in Palo Alto, Calif. The work is outlined in a paper published online Feb. 19 in The Lancet Respiratory Medicine journal. Each year, 9.6 million people worldwide are newly infected with TB, a bacterial infection that usually affects the lungs, and 1.5 million die from the difficult-to-diagnose disease, the researchers noted. "One-third of the world's population is currently infected with TB. Even if only 10 percent of them get active TB, that's still 3 percent of the world's ... Read more

Related support groups: Tuberculosis, Tuberculosis - Latent, Tuberculosis - Active, Pulmonary Tuberculosis, Tuberculosis - Prophylaxis, Diagnosis and Investigation, Tuberculosis - Extrapulmonary, Tuberculosis - HIV Status Unknown, Tuberculous Meningitis, Tuberculosis - Resistant, Tuberculosis - HIV Negative, Tuberculous Esophagitis, Adrenal Tuberculosis, Tuberculosis - HIV Positive, Tuberculosis - Urinary Tract, Ocular Tuberculosis, Tuberculous Pleurisy

TB Cases Falling for Foreign-Born People in U.S.

Posted 10 Feb 2016 by Drugs.com

WEDNESDAY, Feb. 10, 2016 – Tuberculosis cases among foreign-born people in the United States fell by one-fifth in recent years, and the reasons for the decline depend on people's country of origin, a new study suggests. Tuberculosis (TB) is a bacterial infection affecting the lungs and sometimes other organs. Overall, TB cases in the United States decreased over the past two decades, but TB cases among foreign-born people remained higher than in the general population, the study authors said. Between 2007 and 2011, there was a 19 percent drop in TB cases among all foreign-born people in the nation, according to researchers from the U.S. Centers for Disease Control and Prevention. TB cases declined in people recently arriving from Mexico, China, India, the Philippines and Vietnam – the five countries that account for most of the foreign-born people with TB in the United States, the ... Read more

Related support groups: Tuberculosis, Isoniazid, Rifampin, Tuberculosis - Latent, Tuberculosis - Active, Pulmonary Tuberculosis, Tuberculosis - Prophylaxis, Tuberculosis - Extrapulmonary, Rifamate, Rifabutin, Isoniazid/Rifampin, Rifater, Mycobutin, Tuberculosis - Resistant, Rifadin, Tuberculous Meningitis, Tuberculosis - Urinary Tract, Isoniazid/Pyrazinamide/Rifampin, Rimactane, IsonaRif

Toxic Chemicals May Weaken Infants' Response to TB Vaccine

Posted 18 Dec 2015 by Drugs.com

FRIDAY, Dec. 18, 2015 – Exposure to toxic chemicals while in the womb or in early life may weaken a baby's immune system response to the tuberculosis (TB) vaccine, researchers say. The study focused on two common toxins: PCBs, an industrial chemical; and DDT, used in pesticides. These so-called "persistent" pollutants are not easily broken down and remain a health threat years after being banned. PCBs were banned in the United States in 1979. DDT is banned in the United States, but is still used in some countries to control malaria-carrying mosquitoes, the study authors, from the University of Rochester in New York, said in a university news release. The researchers analyzed blood samples and immune responses from 516 pairs of mothers and infants in an area of Slovakia heavily contaminated with environmental toxins. Each baby received the tuberculosis vaccine in their first four days ... Read more

Related support groups: Tuberculosis, BCG, Poisoning, Tuberculosis - Latent, Tuberculosis - Active, Pulmonary Tuberculosis, Tuberculosis - Prophylaxis, Diagnosis and Investigation, Toxic Reactions Incl Drug and Substance Abuse, Tubersol, Tuberculin Purified Protein Derivative, Tuberculosis - Extrapulmonary, Tice BCG, Aplisol, Tice BCG Vaccine, Tuberculosis - Resistant, Tuberculous Meningitis, Tuberculin Tine Test, Vaccination and Prophlaxis, Aplitest

Doctors Save Life of U.S. Child With Drug-Resistant Tuberculosis

Posted 16 Nov 2015 by Drugs.com

SUNDAY, Nov. 15, 2015 – A 5-year-old child from the United States, stricken at age 2 with a deadly form of tuberculosis after traveling to India, is finally in remission, researchers report. The case, one of only a handful reported in the medical literature, highlights the difficulties of treating an extensively drug-resistant form of tuberculosis, known as XDR TB, in children, the researchers said. The case also highlights the growing global threat of this virulent form of TB and the risk to Americans traveling in countries where there is a high burden of disease. A detailed account of the child's diagnosis and treatment, and the obstacles that clinicians at Johns Hopkins Children's Center in Baltimore faced, was published in the Nov. 16 online edition of The Lancet Infectious Diseases. Study co-author Dr. Sanjay Jain, an associate professor of pediatrics and international health at ... Read more

Related support groups: Tuberculosis - Latent, Tuberculosis - Active, Pulmonary Tuberculosis, Diagnosis and Investigation, Computed Tomography, Tuberculosis - Resistant

Swiss Report Highlights Danger of Drug-Resistant Tuberculosis

Posted 11 Nov 2015 by Drugs.com

WEDNESDAY, Nov. 11, 2015 – A new report on a patient in Switzerland who nearly died after catching a highly drug-resistant strain of tuberculosis illustrates exactly what public health officials around the world fear most. Although antibiotics have largely eradicated tuberculosis in the United States in recent decades, experts say evidence is mounting that the bacteria is becoming increasingly resistant to these medications. Details of the Swiss case are reported in the Nov. 12 issue of the New England Journal of Medicine by lead investigator Sebastien Gagneux, head of tuberculosis research with the Swiss Tropical and Public Health Institute at the University of Basel, and colleagues. Normally, Gagneux said, tuberculosis patients are treated for six months with a daily drug "cocktail" comprised of four different first-line medications. The goal: to hem in tuberculosis (TB) while ... Read more

Related support groups: Tuberculosis, Tuberculosis - Latent, Tuberculosis - Active, Pulmonary Tuberculosis, Tuberculosis - Prophylaxis, Tuberculosis - Extrapulmonary, Tuberculous Meningitis, Tuberculosis - Resistant, Bedaquiline, Tuberculous Esophagitis, Adrenal Tuberculosis, Sirturo, Tuberculosis - Urinary Tract, Ocular Tuberculosis, Tuberculous Pleurisy

U.S. Health Officials Search for Those Exposed to Drug-Resistant TB

Posted 9 Jun 2015 by Drugs.com

TUESDAY, June 9, 2015 – U.S. health authorities are trying to find anyone who may have had contact with a woman who has been diagnosed with a highly drug-resistant form of tuberculosis. The woman flew from India to Chicago in April. She then traveled to Missouri and Tennessee before returning to Chicago, where she sought treatment at a hospital about seven weeks after arriving in the United States, The New York Times reported late Monday. At the hospital, the woman was diagnosed with extensively drug-resistant tuberculosis (XDR-TB). On Friday, she was transferred by special air and ground ambulances to a U.S. National Institutes of Health (NIH) hospital in Bethesda, Md. The woman is in an isolation room and the hospital "is providing care and treatment for the patient in connection with an existing NIH clinical protocol for treating TB, including XDR forms," the NIH said. The U.S. ... Read more

Related support groups: Tuberculosis, Tuberculosis - Latent, Tuberculosis - Active, Tuberculosis - Prophylaxis, Tuberculosis - Resistant, Vaccination and Prophlaxis

Could Stem Cells Cure Drug-Resistant Tuberculosis?

Posted 9 Jan 2014 by Drugs.com

THURSDAY, Jan. 9, 2014 – A patient's own bone marrow stem cells might someday be used to treat multidrug-resistant tuberculosis, a new study suggests. The phase 1 study to assess the safety of the treatment included 30 patients, aged 21 to 65, with multidrug-resistant tuberculosis or the even more dangerous extensively drug-resistant tuberculosis. They received standard tuberculosis antibiotic treatment and an infusion of about 10 million of their own bone marrow stem cells. A comparison group of 30 patients with either type of tuberculosis received standard treatment only. After 18 months, 16 patients treated with bone marrow stem cells were cured, compared with five patients in the standard group, the study authors said. The most common side effects in the stem cell group were high cholesterol (14 patients), nausea (11), and lymphopenia (low white blood cell count) or diarrhea (10). ... Read more

Related support groups: Tuberculosis - Resistant

New Test Detects TB and Antibiotic Resistance

Posted 26 Jul 2013 by Drugs.com

FRIDAY, July 26 – A new test to detect bacteria that cause tuberculosis and simultaneously determine if the bacteria are resistant to the antibiotic rifampin has been approved by the U.S. Food and Drug Administration. The Xpert MTB/RIF Assay is less complex to administer than other screening tests for TB. Results are available in about two hours, while traditional methods to detect TB could take up to several months, the agency said in a news release. People with weakened immune systems are most likely to develop full-blown TB once infected with the disease-causing bacteria, the FDA said. TB is a leading killer globally of people with HIV/AIDS. Common symptoms of TB include a severe cough lasting at least three weeks, chest pain, coughing up blood, fatigue and weight loss, the agency said. The test is manufactured and marketed by Cepheid, based in Sunnyvale, Calif. More information The ... Read more

Related support groups: Tuberculosis, Rifampin, Rifadin, Tuberculosis - Resistant, Rifadin IV, Rimactane

TB Drug Shortages Put U.S. Patients in Peril, Study Finds

Posted 17 Jan 2013 by Drugs.com

THURSDAY, Jan. 17 – Shortages of key tuberculosis drugs are posing a real hazard to patients throughout the United States, a new report finds. The shortages are making it even more difficult to treat what's known as multidrug-resistant forms of the infectious respiratory illness, the researchers said. These patients often require so-called "second-line drugs" when the medication of choice fails. For example, the new report cites the 2011 case of a father and his infant child who had each contracted TB. "Despite intensive efforts by public health personnel to obtain the two drugs [needed], the initiation of treatment was delayed by eight days for both patients, prolonging the father's infectious period and thereby increasing the risk for transmission to the community," wrote a team led by Dr. Barbara Seaworth of the University of Texas Health Science Center. Matters were even worse for ... Read more

Related support groups: Tuberculosis, Amikacin, Streptomycin, Kanamycin, Amikin, Amikin Pediatric, Tuberculous Meningitis, Tuberculosis - Resistant, Capreomycin, Capastat Sulfate, Capastat, Kantrex

Sirturo Approved for Multi-Drug Resistant TB

Posted 2 Jan 2013 by Drugs.com

WEDNESDAY, Jan. 2 – Sirturo (bedaquiline) has been approved by the U.S. Food and Drug Administration for use with other drugs to treat multi-drug resistant tuberculosis when alternative treatments aren't available. TB, which is spread through the air, is among the world's deadliest respiratory diseases. Nearly 9 million people worldwide and more than 10,000 in the United States contracted the disease in 2011, the agency said in a news release. The bacterium that causes TB, M. tuberculosis, has become resistant to the powerful drugs isoniazid and rifampin, the FDA added. Sirturo is the first drug approved to treat multi-drug resistant TB, the agency said in its news release. The drug inhibits an enzyme that makes it possible for the tuberculosis bacterium to replicate throughout the body. "Multi-drug resistant tuberculosis poses a serious health threat throughout the world, and Sirturo ... Read more

Related support groups: Tuberculosis - Resistant, Bedaquiline

FDA Approves Sirturo to Treat Multi-Drug Resistant Tuberculosis

Posted 31 Dec 2012 by Drugs.com

December 31, 2012 – On Dec. 28, the U.S. Food and Drug Administration approved Sirturo (bedaquiline) as part of combination therapy to treat adults with multi-drug resistant pulmonary tuberculosis (TB) when other alternatives are not available. TB is an infection caused by Mycobacterium tuberculosis and is one of the world’s deadliest diseases. It is spread from person to person through the air and usually affects the lungs, but it can also affect other parts of the body such as the brain and kidneys. According to the Centers for Disease Control and Prevention, nearly 9 million people around the world and 10,528 people in the United States became sick with TB in 2011. Multi-drug resistant TB occurs when M. tuberculosis becomes resistant to isonazid and rifampin, two powerful drugs most commonly used to treat TB. Sirturo is the first drug approved to treat multi-drug resistant TB and s ... Read more

Related support groups: Tuberculosis, Pulmonary Tuberculosis, Tuberculosis - Resistant

'Alarming' Rise Seen in Drug-Resistant Tuberculosis

Posted 30 Aug 2012 by Drugs.com

THURSDAY, Aug. 30 – There are alarmingly high levels of extensively drug-resistant tuberculosis in many areas of the world, a new study finds. Researchers found high rates of resistance to at least one second-line drug (nearly 44 percent) among multidrug-resistant TB patients in eight countries in Africa, Asia, Europe and Latin America. They also found higher-than-expected overall levels of extensively drug-resistant TB. Multidrug-resistant TB can withstand to at least two first-line drugs: soniazid and rifampicin. Extensively drug-resistant TB is resistant to isoniazid, rifampicin, a fluoroquinolone and a second-line injectable drug. Fluoroquinolones are a class of antibiotics that include ciprofloxacin, levofloxacin and gatifloxacin. For the study, samples collected from nearly 1,300 adults with multidrug-resistant TB in Estonia, Latvia, Peru, the Philippines, Russia, South Africa, ... Read more

Related support groups: Tuberculosis, Tuberculosis - Resistant

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Tuberculosis

Related Drug Support Groups

Sirturo, Paser, bedaquiline, aminosalicylic acid